CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016

ReportsWorldwide has announced the addition of a new report CRISPR/Cas 9 Gene Editing In Drug Discovery Trends 2016 to its growing collection of premium market research reports.

This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on CRISPR/Cas 9 gene editing in drug discovery carried out in February 2016.

The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces.

The questionnaire was compiled to meet the needs, requirements and interests of the gene editing reagents vendor community. The objective was to comprehensively document the current use of CRISPR (clustered regularly interspaced short palindromic repeats) and the associated nuclease Cas 9 in gene editing in drug discovery applications and to understand its future impact.
Equal emphasis was given to soliciting opinion from all areas and organisations where CRISPR/Cas 9 gene editing is being utilised as part of drug discovery efforts.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/crisprcas-9-gene-editing-in-drug-discovery-trends-2016

The survey looked at the following aspects of CRISPR/Cas 9 gene editing technology as practiced today (2016) and in some cases as predicted for the future (2018):

• current experience of gene editing;
• when first started using gene editing;
• extent utilizing in drug discovery;
• number of FTE working in respondent's organisation on gene editing;
• key diseases or research areas using gene editing;
• what respondents want to achieve with gene editing;
• genomes being targeted with gene editing;
• main objectives of gene editing efforts in drug discovery;
• advantages of CRISPR/Cas 9 gene editing technology;
• potential benefits of CRISPR/Cas 9 in drug discovery respondents most want to exploit;
• most relevant features of CRISPR/Cas 9 gene editing technology to respondent's research effort;
• bioinformatics tools used to design guide RNAs (sgRNAs);
• how CRISPR/Cas 9 components are delivered into cells;
• methods used for CRISPR experiments;
• use of different cell types in CRISPR research;
• percentage efficiency of gene editing typically achieved;
• downstream analysis techniques used to validate your CRISPR/Cas 9 gene editing;
• number of sgRNAs designed per gene targeted;
• use of multiplexed gene edits;
• use of CRISPR libraries for target validation or drug mechanism studies and which type of libraries preferred;
• cellular response endpoints of greatest value in the functional screening of CRISPR libraries;
• number of different CRISPR/Cas 9 gene editing projects attempted per year;
• budget for purchasing CRISPR/Cas 9 gene editing related reagents and breakdown into components;
• supplier/vendor that first comes to mind when thinking of CRISPR/Cas 9 gene editing related reagents;
• suppliers where respondents currently purchase the majority of their CRISPR/Cas 9 gene editing related reagents;
• what most limits work on CRISPR/Cas 9 gene editing today;
• and any unmet needs that exist in CRISPR/Cas 9 gene editing related to drug discovery today.

To enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=17

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.